Safety and Pharmacokinetics of Single-Dose Novel Oral Androgen 11β-Methyl-19-Nortestosterone-17β-Dodecylcarbonate in Men
- 24 September 2018
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 104 (3) , 629-638
Abstract
Context 11β-methyl-19-nortestosterone-17β-dodecylcarbonate (11β-MNTDC) is an orally bioavailable prodrug of 11β-methyl-19-nortestosterone (11β-MNT) with androgenic and progestational activity. Objectives 1) Quantify 11β-MNT binding to androgen and progesterone receptors. 2) Evaluate safety, tolerability and serum gonadotropin and testosterone suppression by 11β-MNTDC in men. Design and setting 1) In vitro receptor binding and transactivation studies and 2) Randomized, double-blind, placebo-controlled single dose, dose escalating Phase I study at 2 academic medical centers. Participants and Intervention 12 healthy male volunteers were randomized (5 active:1 placebo) to escalating single oral doses (100, 200, 400, and 800 mg) of 11β-MNTDC or placebo given with or without food. Main outcome measures 1) In vitro 11β-MNT/11β-MNTDC human receptor binding and transactivation and 2) Safety and tolerability, pharmacokinetics, and quantification of serum gonadotropin and testosterone concentrations for 24h following dosing. Results 11β-MNT avidly binds and activates human androgen and progesterone receptors, but 11β-MNTDC has minimal activity. Single oral doses of 11β-MNTDC were well-tolerated without serious adverse events. Administration of 11β-MNTDC with food markedly increased average 11β-MNTDC and 11β-MNT serum concentrations (p<0.001 for all doses) compared to fasting with a significant dose-related effect on average serum drug concentrations (p<0.0001). The 200, 400, and 800 mg doses significantly suppressed average serum testosterone concentrations (p<0.002). Conclusions A single, oral dose of 11β-MNTDC up to 800 mg administered with food is safe and well-tolerated in healthy men. The active drug 11β-MNT has androgenic and progestational activity, rapidly suppresses serum testosterone, and is a promising candidate for an effective once-daily oral male hormonal contraceptive.Keywords
Funding Information
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (HHSN27520130024I, HHSN275201300025I)
- National Center for Advancing Translational Sciences (UL1TR000124, UL1TR000423)
- National Institute of Diabetes and Digestive and Kidney Diseases (5T32 DK007247)
- National Heart, Lung, and Blood Institute (HL138632)
This publication has 42 references indexed in Scilit:
- Male contraceptionBest Practice & Research Clinical Obstetrics & Gynaecology, 2014
- Contraceptive failure in the United StatesContraception, 2011
- Acceptability of contraception for men: a reviewContraception, 2010
- The potent synthetic androgens, dimethandrolone (7α,11β-dimethyl-19-nortestosterone) and 11β-methyl-19-nortestosterone, do not require 5α-reduction to exert their maximal androgenic effectsThe Journal of Steroid Biochemistry and Molecular Biology, 2010
- Dimethandrolone (7α,11β-dimethyl-19-nortestosterone) and 11β-methyl-19-nortestosterone are not converted to aromatic A-ring products in the presence of recombinant human aromataseThe Journal of Steroid Biochemistry and Molecular Biology, 2008
- 7α,11β-Dimethyl-19-nortestosterone: a potent and selective androgen response modulator with prostate-sparing propertiesBioorganic & Medicinal Chemistry Letters, 2005
- Intratesticular Testosterone Concentrations Comparable With Serum Levels Are Not Sufficient to Maintain Normal Sperm Production in Men Receiving a Hormonal Contraceptive RegimenJournal of Andrology, 2004
- A Review of Androgen‐Progestin Regimens for Male ContraceptionJournal of Andrology, 2003
- Contraceptive efficacy of testosterone-induced azoospermia in normal menThe Lancet, 1990
- Clinical trial with testosterone undecanoate for male fertility controlContraception, 1978